Navigation Links
Sorrento Therapeutics Announces Pricing of Public Offering of 4,150,000 Shares of Common Stock and Listing on NASDAQ
Date:10/24/2013

SAN DIEGO, Oct. 24, 2013 /PRNewswire/ -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) announced the pricing of an underwritten public offering of 4,150,000 shares of common stock at an offering price of $7.25 per share.  The shares will begin trading on The NASDAQ Capital Market on October 25, 2013 under the symbol "SRNE." The gross proceeds to Sorrento from this offering are expected to be approximately $30 million, before deducting underwriting discounts and commissions and other estimated offering expenses. The offering is expected to close on or about October 30, 2013, subject to customary closing conditions. Sorrento has granted the underwriters a 45-day option to purchase up to an additional 622,500 shares of common stock to cover over-allotments, if any.

Sorrento intends to use the net proceeds received from the offering to fund its research and development activities, including its registrational clinical trial of Cynviloq™, for working capital, other general corporate purposes, and possibly acquisitions of other companies, products or technologies.

In connection with its listing on The NASDAQ Capital Market, Sorrento's common stock will cease trading on the OTC QB.   

Aegis Capital Corp. is acting as the sole book-running manager for this offering.

CRT Capital is acting as co-manager for this offering. 

A shelf registration statement and accompanying base prospectus on Form S-3 relating to the shares was filed with the Securities and Exchange Commission and is effective.  A preliminary prospectus supplement relating to the offering has been filed with the SEC and is available on the SEC's web site at http://www.sec.gov. Copies of the final prospectus supplement, when available, may be obtained from the SEC's web site or the offices of Aegis C
'/>"/>

SOURCE Sorrento Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Sorrento Therapeutics Secures Rights to Biomiga Diagnostics Therapeutic Drug Monitoring Device for Development of Personalized Paclitaxel Cancer Therapy
2. Sorrento Therapeutics Completes IgDraSol Merger
3. Sorrento Therapeutics to Present at Two Healthcare Conferences
4. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
5. Sorrento Therapeutics and IGDRASOL to Present Late Stage Clinical Data Updates on their Oncology Nanomedicine Platform at the Joint Meeting of the European Foundation for Clinical Nanomedicine and European Technology Platform on Nanomedicine in Base
6. Sorrento Therapeutics Receives Frost & Sullivans Prestigious 2013 Global Investment Opportunity Award in the Oncology Market
7. Sorrento Therapeutics Receives Frost & Sullivans 2013 Global Investment Opportunity Award in Oncology
8. Sorrento Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference in New York City
9. Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases
10. Sorrento Therapeutics, Inc. and IGDRASOL Announce Presentation on Non-Biologic Nanoparticle paclitaxel (NBN-Pac) Formulations for the Treatment of Solid Tumors at the Nanomedicine 2013 Meeting in Barcelona, Spain
11. Sorrento Therapeutics Signs Exclusive Option to Acquire IGDRASOL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... PARK, Calif. , Aug. 31, 2015 /PRNewswire/ ... company focused on the emerging field of regenerative ... successfully dosed at Chicago -based ... clinical trial evaluating activity of escalating doses of ... with sensory and motor complete cervical spinal cord ...
(Date:8/31/2015)... Vascular Ltd., together with its subsidiaries (the "Company" ... the "Group"), a global company engaged in the ... for the minimally invasive treatment of vascular disease, ... ("BTK") cohort of patients in the Chocolate® Balloon ... 15, 2015 at the 5th Annual Amputation Prevention ...
(Date:8/31/2015)... , Aug. 31, 2015 Research ... addition of the "Prescription Pain Drugs - ... Marijuana - Global Markets, Competitors and Opportunities: 2015 ... their offering. Pain is defined ... with actual or potential tissue damage. At some ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 2Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 3Final Results From Below-The-Knee Cohort In Chocolate Registry Presented At The 5th Annual Amputation Prevention Conference 4Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... HARBIN, China , May 18 /PRNewswire-Asia-FirstCall/ -- ... (Nasdaq: CSKI ), a leading fully,integrated pharmaceutical company producing ... today announced record financial results,for the first quarter of 2010. ... Form 10-K for 2009. , , First ...
... HARBIN, China , May 18 ... Board: WKBT) ("Weikang" or the,"Company"), a leading developer, manufacturer ... and other health,and nutritional products in the People,s ... the first quarter of fiscal year 2010 ended on ...
Cached Medicine Technology:China Sky One Medical Announces First Quarter 2010 Results 2China Sky One Medical Announces First Quarter 2010 Results 3China Sky One Medical Announces First Quarter 2010 Results 4China Sky One Medical Announces First Quarter 2010 Results 5China Sky One Medical Announces First Quarter 2010 Results 6China Sky One Medical Announces First Quarter 2010 Results 7China Sky One Medical Announces First Quarter 2010 Results 8China Sky One Medical Announces First Quarter 2010 Results 9China Sky One Medical Announces First Quarter 2010 Results 10China Sky One Medical Announces First Quarter 2010 Results 11China Sky One Medical Announces First Quarter 2010 Results 12China Sky One Medical Announces First Quarter 2010 Results 13China Sky One Medical Announces First Quarter 2010 Results 14Weikang Bio-Technology Reports First Quarter 2010 Financial Results 2Weikang Bio-Technology Reports First Quarter 2010 Financial Results 3Weikang Bio-Technology Reports First Quarter 2010 Financial Results 4Weikang Bio-Technology Reports First Quarter 2010 Financial Results 5Weikang Bio-Technology Reports First Quarter 2010 Financial Results 6Weikang Bio-Technology Reports First Quarter 2010 Financial Results 7Weikang Bio-Technology Reports First Quarter 2010 Financial Results 8Weikang Bio-Technology Reports First Quarter 2010 Financial Results 9Weikang Bio-Technology Reports First Quarter 2010 Financial Results 10Weikang Bio-Technology Reports First Quarter 2010 Financial Results 11
(Date:8/31/2015)... ... August 31, 2015 , ... ITC Global ... of information for specific translation services within the medical and pharmaceutical industries. These ... record of successful work. , ITC Global Translations specializes in professional translation services ...
(Date:8/31/2015)... ... August 31, 2015 , ... Southern Vacation Rentals – a member of the ... South Walton property management company, 360 Blue, in support of the Sonder ... the world. The two companies will collect any unopened food items left in vacation ...
(Date:8/31/2015)... ... August 31, 2015 , ... In an article based on ... author addressed the topic of treating back pain caused by a disrupted disk by ... to slightly improve physical function in patients suffering from a herniated disk, the level ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... recently opened registration for the company’s second Introduction to Hyperbaric Medicine Course. The ... 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. The meeting ...
(Date:8/31/2015)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... by Movestrong, has launched a new weight management program that is unique to ... highly recommended programs in Oakland and Macomb County. , WEmovestrong’s weight management ...
Breaking Medicine News(10 mins):Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 2Health News:GoMarketing Announces Major Updates to ITC Global Translations Website http://www.ITCGlobalTranslations.com 3Health News:Southern Vacation Rentals Partners with the Sonder Project 2Health News:Southern Vacation Rentals Partners with the Sonder Project 3Health News:Article on Steroid Use for Back Pain Highlights the Effectiveness of Surgery in Treating Disk Pain, says Dr. Seyed M. Rezaian 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4
... than 4,400 industry members expected at Natural MarketPlace trade show ... MarketPlace ( www.naturalmarketplaceshow.com ), July 9-11, 2009 ... Hotel, Las Vegas, NV, is expecting a strong attendance of ... over 2008. Produced by New Hope Natural Media in ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) will announce its ... host a conference call and webcast at 9:00 a.m. ... , David P. Holveck, president and chief executive officer, ... officer, Ivan Gergel, M.D., executive vice president of research and ...
... July 1 The International SPA Association 2009 U.S. Spa ... overall spa locations, revenues and visits. While this may ... keep in mind that these numbers are from the calendar ... profitable for many spas. , , Geoff ...
... as a cause, but note that other costs are down ... signed up for Medicare,s prescription drug coverage, called Part D, ... but less on other types of medical care, researchers have ... the New England Journal of Medicine , also found ...
... Study uncovers possible benefit, though, in stemming vision loss, , WEDNESDAY, ... dashed hopes that early use of two blood pressure drugs could ... , But the study, reported in the July 2 issue of ... for the drugs against diabetes-caused eye damage. , Type 1 ...
... response , WEDNESDAY, July 1 (HealthDay News) -- Brain imaging ... study. , Neuroimaging of the anterior cingulate cortex -- ... response -- shows more activity when a person observes someone ... as the same race. The findings, in the July 1 ...
Cached Medicine News:Health News:Demand for Natural Products Drives Strong Attendance 2Health News:Demand for Natural Products Drives Strong Attendance 3Health News:Endo Pharmaceuticals to Announce Second Quarter 2009 Financial Results on July 30, 2009 2Health News:ISPA Releases 2009 U.S. Spa Industry Statistics 2Health News:With Medicare Plan, Drug Spending May Be Up 2Health News:With Medicare Plan, Drug Spending May Be Up 3Health News:Drugs May Not Slow Kidney Damage in Diabetes 2Health News:Shared Race, Social Group Seem to Help People Relate 2
... monitor elevates bedside glucose testing to a ... the quality of central laboratory testing. ... strip technology. Current glucose strips use ... system measures and corrects hematocrit interference as ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
... BreatheX is a wearable CPAP (Continuous Positive ... sleep apnea. The lightweight BreatheX CPAP device ... with its built-in, rechargeable battery, and is ... no longer need to be "plugged in ...
Paraffin Block Storage System...
Medicine Products: